Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MRNA-4157 by Moderna for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
MRNA-4157 by Moderna for Gastric Cancer: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MRNA-4157 by Moderna for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
MRNA-4157 is under clinical development by Moderna and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According...
MRNA-1083 by Moderna for Influenzavirus B Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenzavirus B Infections. According to GlobalData, Phase...
MRNA-1083 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections. According...
MRNA-1045 by Moderna for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
MRNA-1045 is under clinical development by Moderna and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to...
MRNA-1230 by Moderna for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
MRNA-1230 is under clinical development by Moderna and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to...
MRNA-1215 by Moderna for Nipah Virus (NiV) Infections: Likelihood of Approval
MRNA-1215 is under clinical development by Moderna and currently in Phase I for Nipah Virus (NiV) Infections. According to GlobalData,...
MRNA-1011.1 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1011.1 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1011.2 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1011.2 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1012.1 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1012.1 is under clinical development by Moderna and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II...
MRNA-1010 by Moderna for Seasonal Influenza: Likelihood of Approval
MRNA-1010 is under clinical development by Moderna and currently in Phase III for Seasonal Influenza. According to GlobalData, Phase III...
MRNA-1083 by Moderna for Influenzavirus B Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenzavirus B Infections. According to GlobalData, Phase...
MRNA-1083 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H1N1 Subtype Infections. According...
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
MRNA-1083 is under clinical development by Moderna and currently in Phase II for Influenza A Virus, H3N2 Subtype Infections. According...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-3705?
MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-1010?
MRNA-1010 is a mrna vaccine commercialized by Moderna, with a leading Phase III program in Influenzavirus B Infections. According to...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-3927?
MRNA-3927 is a gene therapy commercialized by Moderna, with a leading Phase II program in Propionic Acidemia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-1647?
MRNA-1647 is a mrna vaccine commercialized by Moderna, with a leading Phase III program in Cytomegalovirus (HHV-5) Infections. According to...